Bukwang Pharmaceutical: Lurasidone shows average 2 kg 라이브 바카라사이트 loss over 16 weeks in bipolar disorder

[by Ji, Yong Jun] Bukwang Pharmaceutical announced on February 23 that a Korean study confirmed clinical evidence suggesting that antipsychotic therapy for bipolar disorder may mitigate metabolic adverse effects (라이브 바카라사이트 gain).

According to Bukwang Pharmaceutical, Professor Kim Young-chan of the Catholic University of Korea St. Vincent's Hospital presented the findings of a retrospective observational study assessing the efficacy and safety profile of 라이브 바카라사이트 at the 2026 Korean Society of Psychiatry Annual Conference, held at the Korean Federation of Science and Technology Societies on February 22.

The study findings indicated that patients with bipolar disorder who transitioned from prior medication to Latuda (lurasidone) and were treated for 16 weeks experienced a reduction in body 라이브 바카라사이트. Specifically, patients who switched to lurasidone demonstrated an average 라이브 바카라사이트 loss of 2.06 kg (approximately 2.8%) relative to baseline at 16 weeks. Beyond the primary efficacy endpoint of 라이브 바카라사이트 change, statistically significant improvements were also observed in broader physical and psychiatric parameters, including body mass index (BMI), the Hamilton Depression Rating Scale (HAM-D), and the Clinical Global Impression-Severity and Improvement scales (CGI-S/I).

When analyzing the primary efficacy endpoint, body 라이브 바카라사이트 change, stratified by prior medication, patients previously treated with aripiprazole (-1.99 kg), olanzapine (-2.4 kg), and quetiapine (-2.4 kg) all demonstrated statistically significant 라이브 바카라사이트 reductions after 16 weeks of treatment.

"Metabolic syndrome induced by antipsychotic medications is a major contributor to reduced treatment adherence and subsequent discontinuation. The findings of this study indicate that Latuda effectively alleviates depressive symptoms while also serving as a reliable treatment option for patients with bipolar disorder who are concerned about weight gain," Kim said.

The metabolic neutrality of lurasidone has been consistently supported by multiple global data sets. A short-term, six-week clinical trial published in the American Journal of Psychiatry in 2014 reported that lurasidone, administered either as monotherapy or in combination therapy, was associated with 라이브 바카라사이트 gains that were not statistically significant compared to placebo.

A 2017 study published in Annals of General Psychiatry reported that patients treated with lurasidone experienced a mean 라이브 바카라사이트 reduction of 0.77 kg over one year. Additionally, another study demonstrated that patients who transitioned from second-generation antipsychotics associated with high risk of 라이브 바카라사이트 gain, such as clozapine or olanzapine, to lurasidone achieved an average 라이브 바카라사이트 loss of 1.68 kg.

"This announcement reaffirms the potential of lurasidone as a viable alternative for patients who have experienced difficulty maintaining treatment due to metabolic side effects, offering both weight management benefits and effective symptom control," a Bukwang Pharmaceutical official said.